Should You Invest $1,000 in Eli Lilly today?
Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. The pharma giant's presence across several treatment areas has helped it grow earnings over time. But, in recent years, one particular product portfolio has stood out and driven double-digit revenue growth: drugs to help people lose weight.Right now, Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss, though doctors have prescribed either one for patients hoping to shed pounds. Mounjaro and Zepbound each have become blockbusters, bringing in billion-dollar revenue annually. Lilly dominates the weight loss market along with rival Novo Nordisk, but a recent move by Lilly could help it push farther ahead in the coming years.Considering this, should you invest $1,000 in Lilly stock today? Let's find out.Continue reading
Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. The pharma giant's presence across several treatment areas has helped it grow earnings over time. But, in recent years, one particular product portfolio has stood out and driven double-digit revenue growth: drugs to help people lose weight.
Right now, Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss, though doctors have prescribed either one for patients hoping to shed pounds. Mounjaro and Zepbound each have become blockbusters, bringing in billion-dollar revenue annually. Lilly dominates the weight loss market along with rival Novo Nordisk, but a recent move by Lilly could help it push farther ahead in the coming years.
Considering this, should you invest $1,000 in Lilly stock today? Let's find out.
